GSK wins FDA accelerated approval for neladalkib, a lung cancer therapy from the Nuvalent acquisition
FROM THE WIRE · SEEKINGALPHA.COM
[GSK -Glaxosmithkline headquarters office building in Poznan.] Magdalena Wygralak The U.S. Food and Drug Administration on Tuesday granted accelerated approval to neladalkib, a lung cancer therapy now owned by GSK (GSK [https://seekingalpha.com/symbol/GSK]), following its $10.6B…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishThe early approval strengthens GSK's oncology pipeline following its $10.6 billion acquisition of Nuvalent.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The FDA granted accelerated approval to neladalkib, a kinase inhibitor.
- 02The approval covers adults with locally advanced or metastatic non-small cell lung cancer, as a late-line option.
- 03The decision came ahead of the November 27 target action date set for Nuvalent's application.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets